Joon Young Hur

556 total citations
26 papers, 346 citations indexed

About

Joon Young Hur is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Joon Young Hur has authored 26 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Immunology and 6 papers in Surgery. Recurrent topics in Joon Young Hur's work include Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Joon Young Hur is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Joon Young Hur collaborates with scholars based in South Korea, United States and Puerto Rico. Joon Young Hur's co-authors include Se‐Hoon Lee, Bo Mi Ku, Jin Seok Ahn, Keunchil Park, Jong‐Mu Sun, Jiae Koh, Myung‐Ju Ahn, Youjin Kim, Seok Jin Kim and Sang Eun Yoon and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Joon Young Hur

23 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joon Young Hur South Korea 10 238 139 84 54 49 26 346
Ignazio Martellucci Italy 11 280 1.2× 67 0.5× 110 1.3× 64 1.2× 36 0.7× 16 356
Fernanda Pilataxi United States 8 195 0.8× 199 1.4× 104 1.2× 46 0.9× 57 1.2× 15 383
Sho Tachino Japan 5 258 1.1× 112 0.8× 104 1.2× 58 1.1× 92 1.9× 6 410
Byung Woog Kang South Korea 10 241 1.0× 88 0.6× 193 2.3× 66 1.2× 41 0.8× 21 406
M Tomšová Czechia 7 251 1.1× 190 1.4× 61 0.7× 32 0.6× 22 0.4× 22 387
Félix Blanc‐Durand France 11 171 0.7× 64 0.5× 89 1.1× 103 1.9× 50 1.0× 40 303
Xin-Ke Zhang China 7 215 0.9× 78 0.6× 118 1.4× 65 1.2× 24 0.5× 9 359
Longgang Cui China 7 297 1.2× 65 0.5× 159 1.9× 61 1.1× 31 0.6× 17 383
Yalun Li China 12 164 0.7× 82 0.6× 163 1.9× 117 2.2× 25 0.5× 39 412
Yayan Zhang United States 7 331 1.4× 148 1.1× 78 0.9× 65 1.2× 142 2.9× 10 440

Countries citing papers authored by Joon Young Hur

Since Specialization
Citations

This map shows the geographic impact of Joon Young Hur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joon Young Hur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joon Young Hur more than expected).

Fields of papers citing papers by Joon Young Hur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joon Young Hur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joon Young Hur. The network helps show where Joon Young Hur may publish in the future.

Co-authorship network of co-authors of Joon Young Hur

This figure shows the co-authorship network connecting the top 25 collaborators of Joon Young Hur. A scholar is included among the top collaborators of Joon Young Hur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joon Young Hur. Joon Young Hur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hur, Joon Young, Kyueng‐Whan Min, Yung‐Kyun Noh, et al.. (2024). CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma. Current Medicinal Chemistry. 32(12). 2409–2421.
2.
3.
Noh, Yung‐Kyun, Kyueng‐Whan Min, Dong Hoon Kim, et al.. (2024). p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis. Journal of Breast Cancer. 27(5). 305–305.
4.
Lee, Ji Yun, Ji Hyun Kwon, Joon Young Hur, et al.. (2023). Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Research and Treatment. 56(2). 681–687. 4 indexed citations
5.
Choi, Jung‐Hye, Joon Young Hur, & Young‐Woong Won. (2023). Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib. Cancer Research and Treatment. 55(2). 704–705. 2 indexed citations
6.
Park, Inkeun, In-Ho Kim, Joon Young Hur, et al.. (2022). Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Current Problems in Cancer. 46(3). 100848–100848. 8 indexed citations
7.
8.
Hur, Joon Young, Sang Eun Yoon, Darae Kim, et al.. (2021). Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis. Blood Research. 56(4). 266–278. 1 indexed citations
9.
Jeong, Hyehyun, Motoko Yamaguchi, Insuk Sohn, et al.. (2020). Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 136(22). 2548–2556. 17 indexed citations
10.
Byeon, Seonggyu, Jinchul Kim, Minsuk Kwon, et al.. (2020). Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. Investigative and Clinical Urology. 61(6). 588–588. 4 indexed citations
11.
Hur, Joon Young, Bo Mi Ku, Joonho Shim, et al.. (2020). Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping. In Vivo. 34(3). 1399–1406. 15 indexed citations
12.
Hur, Joon Young, Yeon Jeong Kim, Sang Eun Yoon, et al.. (2020). Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. Annals of Hematology. 99(6). 1293–1302. 19 indexed citations
13.
Hur, Joon Young, Sang Eun Yoon, Seok Jin Kim, & Won Seog Kim. (2020). Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study. Blood Research. 55(2). 85–90. 4 indexed citations
14.
Hur, Joon Young, Joseph Chao, Kyung Kim, et al.. (2020). High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology - Research and Practice. 216(4). 152878–152878. 24 indexed citations
15.
Koh, Jiae, Joon Young Hur, Bo Mi Ku, et al.. (2020). Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports. 10(1). 18994–18994. 66 indexed citations
16.
Koh, Jiae, Youjin Kim, Joon Young Hur, et al.. (2020). MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC. European Journal of Immunology. 50(11). 1810–1819. 68 indexed citations
17.
Hur, Joon Young, et al.. (2020). Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. Journal of Cancer. 11(10). 2800–2807. 9 indexed citations
18.
Hur, Joon Young, Minyong Kang, Hyun Hwan Sung, et al.. (2019). Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. Cancer Research and Treatment. 51(4). 1269–1274. 3 indexed citations
19.
Choi, Gyu‐Seong, Dohern Kim, Joon Young Hur, et al.. (2004). Deep Vein Thrombosis at Lower Extremities in Severe Burn Patients. 20(1). 106–110. 3 indexed citations
20.
Oh, Min‐Jeong, Jin-Hyuk Choi, Yong‐ho Lee, et al.. (2003). Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance. Cancer Letters. 203(1). 107–112. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ignazio Martellucci Breakdown of academic impact, for papers by Fernanda Pilataxi Breakdown of academic impact, for papers by Sho Tachino Breakdown of academic impact, for papers by Byung Woog Kang Breakdown of academic impact, for papers by M Tomšová Breakdown of academic impact, for papers by Félix Blanc‐Durand Breakdown of academic impact, for papers by Xin-Ke Zhang Breakdown of academic impact, for papers by Longgang Cui Breakdown of academic impact, for papers by Yalun Li Breakdown of academic impact, for papers by Yayan Zhang
Rankless by CCL
2026